领航医药：根据一般授权配售新股份失效

Group 1 - The core point of the article is that Vanguard Pharmaceuticals announced the expiration of a share placement agreement due to unmet conditions, which will not adversely affect the company's operations or financial status [1][1][1] Group 2 - The company had entered into a placement agreement with China Northern Securities Group on August 21, 2025, to issue up to 145,000,000 shares at a price of HKD 0.415 per share [1][1][1] - The placement was authorized by the shareholders' meeting, but it has now been confirmed that it cannot be completed [1][1][1] - The company primarily engages in pharmaceutical and biotechnology-related businesses [1][1][1]